[1]何 钰,王建波,王 武.内动脉粥样硬化性狭窄支架植入术后再狭窄机制及治疗新进展[J].介入放射学杂志,2021,30(11):1184-1189.
 HE Yu,WANG Jianbo,WANG Wu.The mechanism of restenosis in patients with intracranial atherosclerotic stenosis after receiving stent implantation and the latest progress in its clinical treatment[J].journal interventional radiology,2021,30(11):1184-1189.
点击复制

内动脉粥样硬化性狭窄支架植入术后再狭窄机制及治疗新进展()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
30
期数:
2021年11
页码:
1184-1189
栏目:
综述
出版日期:
2021-11-25

文章信息/Info

Title:
The mechanism of restenosis in patients with intracranial atherosclerotic stenosis after receiving stent implantation and the latest progress in its clinical treatment
作者:
何 钰 王建波 王 武
Author(s):
HE Yu WANG Jianbo WANG Wu
Department of Interventional Radiology, Shanghai Municipal Sixth People’s Hospital, Shanghai 200233, China
关键词:
【关键词】 颅脑动脉 动脉粥样硬化 支架 再狭窄 血管内治疗
文献标志码:
A
摘要:
【摘要】 颅内动脉粥样硬化性狭窄(ICAS)是缺血性脑卒中的主要病因。随着脑血管介入治疗理念和材料不断发展,脑血管介入支架已成为ICAS首选治疗策略。但支架植入后支架内再狭窄(ISR)问题异常突出,其原因和机制较为复杂,涉及内皮细胞和平滑肌细胞过度增殖及再次动脉粥样硬化形成。目前ICAS介入治疗的重点和难点仍然是术后ISR预防和治疗。该文主要综述ICAS支架植入术后ISR机制和血管内再介入治疗研究进展及展望,旨在为临床治疗决策提供新思考和方向。

参考文献/References:

[1] Qureshi AI, Caplan LR. Intracranial atherosclerosis[J]. Lancet, 2014, 383: 984- 998.
[2] Wang Y, Zhao X, Liu L,et al. Prevalence and outcomes of symptomatic intracranial large artery stenoses and occlusions in China: the Chinese Intracranial Atherosclerosis(CICAS) Study[J]. Stroke, 2014, 45: 663-669.
[3] Wang Y, Meng R, Liu G,et al. Intracranial atherosclerotic disease[J]. Neurobiol Dis, 2019, 124: 118-132.
[4] Alfonso F, Perez-Vizcayno MJ, Cardenas A,et al. A prospective randomized trial of drug- eluting balloons versus everolimus-eluting stents in patients with in- stent restenosis of drug- eluting stents: the RIBS Ⅳ randomized clinical trial[J]. J Am Coll Cardiol, 2015, 66: 23-33.
[5] Sun X, Ma N, Wang B,et al. The long term results of vertebral artery ostium stenting in a single center[J]. J Neurointerv Surg, 2015, 7: 888-891.
[6] Lopez- Cancio E, Galan A, Dorado L,et al. Biological signatures of asymptomatic extra- and intracranial atherosclerosis: the Barcelona- AsIA(Asymptomatic Intracranial Atherosclerosis) study[J]. Stroke, 2012, 43: 2712-2719.
[7] Dang M, Song Y, Li Q,et al. Genetic variation of the kalirin gene is associated with ICAS in the Chinese population[J]. J Mol Neurosci, 2018, 66: 157-162.
[8] Wu JH, Fanaroff AC, Sharma KC,et al. Kalirin promotes neointimal hyperplasia by activating Rac in smooth muscle cells[J]. Arterioscler Thromb Vasc Biol, 2013, 33: 702-708.
[9] Stary HC, Chandler AB, Glagov S,et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arte-riosclerosis,American Heart Association[J]. Circulation, 1994, 89: 2462-2478.
[10] Papanagiotou P, Roth C, Walter S,et al. Carotid artery stenting in acute stroke[J]. J Am Coll Cardiol, 2011, 58: 2363-2369.
[11] Cohen DJ, Stolker JM, Wang K,et al. Health-related quality of life after carotid stenting versus carotid endarterectomy: results from CREST(Carotid Revascularization Endarterectomy Versus Stenting Trial)[J]. J Am Coll Cardiol, 2011, 58: 1557-1565.
[12] Brott TG, Hobson RW 2nd, Howard G,et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis[J]. N Engl J Med, 2010, 363: 11-23.
[13] Derdeyn CP, Chimowitz MI, Lynn MJ,et al. Aggressive medical treatment with or without stenting in high- risk patients with intracranial artery stenosis(SAMMPRIS): the final results of a randomised trial[J]. Lancet, 2014, 383: 333-341.
[14] Shlofmitz E, Iantorno M, Waksman R. Restenosis of drug-eluting stents: a new classification system based on disease mechanism to guide treatment and state-of-the-art review[J]. Circ Cardiovasc Interv, 2019, 12: e007023.
[15] Jensen LO, Vikman S, Antonsen L,et al. Intravascular ultrasound assessment of minimum lumen area and intimal hyperplasia in in- stent restenosis after drug- eluting or bare- metal stent implantation. The Nordic Intravascular Ultrasound Study(NIVUS)[J]. Cardiovasc Revasc Med, 2017, 18: 577-582.
[16] Arbustini E, Favalli V, Narula J. Functionally incomplete re-endothelialization of stents and neoatherosclerosis[J]. JACC Cardiovasc Interv, 2017, 10: 2388-2391.
[17] Zhao LP, Xu WT, Wang L,et al. Influence of insulin resistance on in- stent restenosis in patients undergoing coronary drug- eluting stent implantation after long- term angiographic follow- up[J]. Coron Artery Dis, 2015, 26: 5-10.
[18] Zhou Z, Yin Q, Xu G,et al. Influence of vessel size and tortuosity on in- stent restenosis after stent implantation in the vertebral artery ostium[J]. Cardiovasc Intervent Radiol, 2011, 34: 481- 487.
[19] Muller MD, Gregson J, McCabe DJH,et al. Stent design, restenosis and recurrent stroke after carotid artery stenting in the international carotid stenting study[J]. Stroke, 2019, 50: 3013-3020.
[20] 刘晓哲, 王 兵, 刘俊超,等. 药物涂层球囊在股腘动脉支架内再狭窄治疗中的应用[J]. 介入放射学杂志, 2018, 27: 410-414.
[21] Strobel HA, Qendro EI, Alsberg E,et al. Targeted delivery of bioactive molecules for vascular intervention and tissue engineering[J]. Front Pharmacol, 2018, 9: 1329.
[22] Chu J, Chen L, Mo Z,et al. An atorvastatin calcium and poly(L-lactide- co- caprolactone) core- shell nanofiber- covered stent to treat aneurysms and promote reendothelialization[J]. Acta Biomater, 2020, 111: 102-117.
[23] Zhang Y, Wang J, Xiao J,et al. An electrospun fiber-covered stent with programmable dual drug release for endothelialization acceleration and lumen stenosis prevention[J]. Acta Biomater, 2019, 94: 295-305.
[24] Power S, Slattery MM, Lee MJ. Nanotechnology and its relationship to interventional radiology. Part Ⅱ: drug delivery, thermotherapy, and vascular intervention[J]. Cardiovasc Intervent Radiol, 2011, 34: 676-690.
[25] Liu P, Liu Y, Li P,et al. Rosuvastatin- and heparin- loaded poly(l- lactide- co- caprolactone) nanofiber aneurysm stent promotes endothelialization via vascular endothelial growth factor type A modulation[J]. ACS Appl Mater Interfaces, 2018, 10: 41012- 41018.
[26] Luderer F, Lobler M, Rohm HW,et al. Biodegradable sirolimus-loaded poly(lactide) nanoparticles as drug delivery system for the prevention of in- stent restenosis in coronary stent application[J]. J Biomater Appl, 2011, 25: 851-875.
[27] Ali RM, Abdul Kader MASK, Wan Ahmad WA, et al. Treatment of coronary drug- eluting stent restenosis by a sirolimus- or paclitaxel- coated balloon[J]. JACC Cardiovasc Interv, 2019, 12: 558-566.
[28] Yamagami H, Sakai N, Matsumaru Y,et al. Periprocedural cilostazol treatment and restenosis after carotid artery stenting: the Retrospective Study of In- Stent Restenosis after Carotid Artery Stenting(ReSISteR- CAS)[J]. J Stroke Cerebrovasc Dis, 2012, 21: 193-199.
[29] Lammer J, Zeller T, Hausegger KA,et al. Heparin- bonded covered stents versus bare- metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial[Viabahn endoprosthesis with PROPATEN bioactive surface(VIA) versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease][J]. J Am Coll Cardiol, 2013, 62: 1320-1327.
[30] Zhou L, Liu D, Li Y,et al. Argatroban for preventing occlusion and restenosis after extracranial artery stenting[J]. Eur Neurol, 2014, 71: 319-325.
[31] Shi R, Zhang R, Yang F,et al . Tissue kallikrein prevents restenosis after stenting of severe atherosclerotic stenosis of the middle cerebral artery:a randomized controlled trial[J]. Medicine(Baltimore), 2016, 95: e2809.
[32] Kuang H, Wang Y, Hu J,et al. A method for preparation of an internal layer of artificial vascular graft co- modified with salvianolic acid B and heparin[J]. ACS Appl Mater Interfaces, 2018, 10: 19365-19372.
[33] Zhang F, Zhang Q, Li X,et al. Mussel-inspired dopamine- CuⅡcoatings for sustained in situ generation of nitric oxide for prevention of stent thrombosis and restenosis[J]. Biomaterials, 2019, 194: 117-129.
[34] Park J, Seo H, Hwang HW,et al. Interface engineering of fully metallic stents enabling controllable H2O2 generation for antires-tenosis[J]. Langmuir, 2019, 35: 3634-3642.
[35] Gao J, Jiang L, Liang Q,et al. The grafts modified by hepari-nization and catalytic nitric oxide generation used for vascular implantation in rats[J]. Regen Biomater, 2018, 5: 105-114.
[36] Huang C, Zhou M, Zheng X. RhoA inhibitor- eluting stent attenuates restenosis by inhibiting YAP signaling[J]. J Vasc Surg, 2019, 69: 1581-1589.e1.
[37] 郑 辉, 郭富强. Rho/Rho激酶信号通路与支架内再狭窄的研究[J]. 介入放射学杂志, 2012, 21: 172-175
[38] Wen M, Zhi D, Wang L,et al. Local delivery of dual microRNAs in trilayered electrospun grafts for vascular regeneration[J]. ACS Appl Mater Interfaces, 2020, 12: 6863-6875.
[39] Nestelberger T, Kaiser C, Jeger R. Drug- coated balloons in cardiovascular disease: benefits, challenges, and clinical appli-cations[J]. Expert Opin Drug Deliv, 2020, 17: 201-211.
[40] 曾书燚, 王正东, 陈 坚,等. 药物洗脱球囊与药物洗脱支架治疗支架内再狭窄疗效比较[J]. 介入放射学杂志, 2017, 26: 839-842.
[41] He C, Wang S, Zhou X,et al. A Review on the comparison of different treatments for carotid in-stent restenosis[J]. Can J Neurol Sci, 2019, 46: 666- 681.
[42] 张成超, 谷涌泉, 齐立行,等. 药物涂层球囊扩张成形术治疗颈动脉支架内再狭窄2例[J]. 介入放射学杂志, 2019, 28: 159-161.
[43] den Dekker WK, Houtgraaf JH, Onuma Y,et al. Final results of the HEALING IIB trial to evaluate a bio- engineered CD34 antibody coated stent(GenousStent) designed to promote vascular healing by capture of circulating endothelial progenitor cells in CAD patients[J]. Atherosclerosis, 2011, 219: 245-252.
[44] Saleh YE, Gepreel MA, Allam NK. Functional nanoarchitectures for enhanced drug eluting stents[J]. Sci Rep, 2017, 7: 40291.
[45] Adeel MY, Sharif F. Advances in stent-mediated gene delivery[J]. Expert Opin Drug Deliv, 2016, 13: 465- 468.
[46] Cornelissen A, Vogt FJ. The effects of stenting on coronary endothelium from a molecular biological view: time for impro- vement?[J]. J Cell Mol Med, 2019, 23: 39- 46.
[47] Goel SA, Guo LW, Liu B,et al. Mechanisms of post-intervention arterial remodelling[J]. Cardiovasc Res, 2012, 96: 363-371.
[48] Inoue T, Croce K, Morooka T,et al. Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis[J]. JACC Cardiovasc Interv, 2011, 4: 1057-1066.
[49] Chen Y, Gao L, Qin Q,et al. Comparison of 2 different drug- coated balloons in in- stent restenosis: the RESTORE ISR China randomized trial[J]. JACC Cardiovasc Interv, 2018, 11: 2368-2377.

相似文献/References:

[1]徐迎佳,方唯一,杨向军.冠脉钙化小结血管内超声影像识别、发生率和分布特征[J].介入放射学杂志,2011,(08):606.
 XU Ying-jia,FANG Wei-yi,YANG Xiang-jun..The occurrence and distribution features of calcified nodules in coronary arteries determined by intravascular ultrasonography[J].journal interventional radiology,2011,(11):606.
[2]黄志志.椎动脉硬化性闭塞介入再通一例[J].介入放射学杂志,2013,(04):345.
 HUANG Zhi- zhi..Re- canalization of vertebral arteriosclerotic occlusion with stent implantation: report of one case[J].journal interventional radiology,2013,(11):345.
[3]梅百强,杨希立,许兆延,等.H型高血压患者斑块特征与同型半胱氨酸相关性研究 [J].介入放射学杂志,2016,(01):70.
 MEI Bai- qiang,YANG Xi- li,XU Zhao- yan,et al.Study on the relationship between plaque imaging characteristics and homocysteine in patients with H- type hypertension [J].journal interventional radiology,2016,(11):70.
[4]岑锦明,杨希立,许兆延,等.iMapTM血管内超声检测冠状动脉粥样斑块坏死核心与心血管疾病危险因素、Lp- PLA2相关性[J].介入放射学杂志,2018,27(12):1134.
 CEN Jinming,YANG Xili,XU Zhaoyan,et al.The relationship of coronary atherosclerotic plaque necrosis core measured by iMapTM intravascular ultrasound to cardiovascular disease risk factors and LP- PLA2[J].journal interventional radiology,2018,27(11):1134.

备注/Memo

备注/Memo:
(收稿日期:2020-06-18)
(本文编辑:边 佶)
更新日期/Last Update: 2021-11-22